Opdivo
Bristol Myers Squibb and Pfizer Unveil Promising Colorectal Cancer Treatments at ASCO GI 2025
Colorectal cancer, metastatic colorectal cancer, Bristol Myers Squibb, Pfizer, Opdivo, Yervoy, Braftovi, ASCO GI 2025, cancer treatment, immunotherapy.
FDA Approves BMS’ Opdivo for Perioperative Treatment of Resectable Non-Small Cell Lung Cancer
Opdivo (nivolumab), Perioperative treatment, Resectable non-small cell lung cancer (NSCLC), FDA approval, CheckMate-77T trial, Neoadjuvant and adjuvant therapy
Top 10 Pharmaceutical Drug Ad Spenders: A Review of the Latest Rankings
pharmaceutical drug ad spenders, top 10, AbbVie, Skyrizi, Rexulti, Dupixent, Rinvoq, Vraylar, Sotyktu, Jardiance, Ozempic, Caplyta, Opdivo
FDA Greenlights Opdivo Combination Therapy for First-Line Bladder Cancer Treatment
Overall Survival, Combined, cisplatin, Opdivo
Bristol Myers’ Opdivo fails part two of post-kidney cancer surgery test as competitor Merck touts new survival data
Bristol, Myers, Opdivo, post-kidney cancer surgery test, Continuance of life